TEAD1 (TEA Domain Transcription Factor 1), also known as transcription factor TEAD-1 or NTEF-1, is a member of the TEA domain (TEA/ATTS) transcription factor family. TEAD1 is a key effector of the Hippo signaling pathway and plays critical roles in development, tissue homeostasis, and cell fate determination. In the nervous system, TEAD1 regulates neurogenesis, neuronal survival, synaptic function, and is implicated in neurodegenerative diseases including Alzheimer's disease and Parkinson's disease.
¶ Gene and Protein Structure
| Attribute |
Value |
| Gene Symbol |
TEAD1 |
| Full Name |
TEA Domain Transcription Factor 1 |
| Alternative Names |
TEF-1, ETF, NTEF, TEAD |
| Chromosomal Location |
11p15.4 |
| NCBI Gene ID |
7003 |
| Ensembl ID |
ENSG00000187091 |
| UniProt ID |
P28347 |
| OMIM |
189892 |
| Protein Class |
Transcription factor; Hippo pathway effector |
| Associated Diseases |
Alzheimer's disease, Parkinson's disease, cancer, Svevo syndrome |
The TEAD1 gene spans approximately 50 kb and consists of 16 exons encoding a 426-amino acid protein. The gene undergoes alternative splicing to generate multiple isoforms with tissue-specific expression patterns:
- TEAD1-1 — Full-length isoform (426 aa), ubiquitous expression
- TEAD1-2 — Alternative splicing isoform with different C-terminus
- TEAD1-3 — Brain-enriched isoform
- TEAD1-4 — Muscle-specific isoform
TEAD1 contains distinct functional domains:
¶ TEA Domain (1-60)
- DNA-binding domain
- Recognizes MCAT consensus sequences (5'-CTTYWAY-3')
- Also called ATTS domain
- Mediates nuclear localization and protein-protein interactions
¶ Transcriptional Activation Domain (60-200)
- Mediates interaction with co-activators
- Contains YAP/TAZ binding site (200-400)
- Proline-rich region
¶ YAP/TAZ Binding Domain (200-350)
- Critical for Hippo pathway signaling
- Forms complex with YAP/TAZ
- Regulated by Hippo pathway kinases
¶ C-terminal Domain (350-426)
- Dimerization interface
- Protein-protein interactions
- Regulatory modifications
TEAD1 activity is regulated by several modifications:
- Phosphorylation: Tyrosine and serine phosphorylation affects DNA binding and interactions
- Acetylation: Lysine acetylation modulates transcriptional activity
- Sumoylation: SUMO modification influences nuclear-cytoplasmic trafficking
- Ubiquitination: Regulates protein stability and degradation
TEAD1 is the central effector of the Hippo pathway:
- YAP/TAZ partnership — Forms transcriptional complexes with YAP/TAZ
- DNA binding — TEAD1 binds DNA, YAP/TAZ provide transcriptional activation
- Target gene regulation — Controls genes for proliferation, survival, differentiation
- Pathway crosstalk — Interacts with Wnt, Notch, and TGF-β pathways
TEAD1 regulates cell cycle genes:
- Cyclin expression — Controls cyclin D1, cyclin E
- Cell cycle arrest — Mediates contact inhibition
- Proliferation signals — Responds to growth factor signaling
- Tissue size control — Limits organ size through Hippo activation
TEAD1 influences apoptosis and survival:
- Anti-apoptotic genes — Activates survivin, Bcl-2 family
- Pro-apoptotic regulation — Can repress pro-death genes
- Stress responses — Handles oxidative stress, DNA damage
- Autophagy regulation — Links to autophagy pathways
TEAD1 has specialized roles in different tissues:
- Heart development — Essential for cardiogenesis
- Muscle differentiation — Myogenesis regulator
- Neural development — Neuronal specification and migration
¶ Brain Expression and Function
TEAD1 is widely expressed in the brain with specific patterns:
- Cerebral cortex: High expression in pyramidal neurons across all layers
- Hippocampus: Particularly enriched in CA1 and CA3 pyramidal cells
- Cerebellum: Purkinje cells show strong TEAD1 expression
- Subventricular zone: Neural stem cells express TEAD1
- Olfactory bulb: Mitral and tufted cells
TEAD1 is also expressed in glial cells:
- Astrocytes: TEAD1 regulates astrocyte proliferation and reactivity
- Oligodendrocytes: Controls oligodendrocyte differentiation and myelination
- Microglia: Modulates microglial activation and neuroinflammation
TEAD1 regulates numerous target genes in the nervous system:
- Cell cycle regulators: cyclin D1, cyclin E, p21, p27
- Survival proteins: survivin, Bcl-2, MCL-1
- Cytoskeletal proteins: actin, tubulin, MAPs
- Synaptic proteins: synapsin, PSD-95, NMDA receptors
- Metabolic enzymes: glycolysis and mitochondrial genes
TEAD1 activity is regulated by multiple signaling pathways:
- Hippo pathway kinases: LATS1/2 phosphorylate YAP/TAZ, preventing their nuclear entry
- Wnt signaling: β-catenin can interact with TEAD1 complexes
- Notch pathway: Cross-talk affects TEAD1 transcriptional activity
- PI3K/Akt signaling: Modulates YAP nuclear localization
TEAD1 requires co-factors for transcriptional activity:
- YAP/TAZ: Primary co-activators, form complexes with TEAD1
- VGLL proteins: Vestigial-like proteins can compete with YAP/TAZ
- p300/CBP: Histone acetyltransferases for transcriptional activation
- SMADs: TGF-β pathway effectors can cooperate with TEAD1
TEAD1 subcellular distribution is tightly regulated:
- Nuclear localization: Active transcription factor in nucleus
- Cytoplasmic sequestration: Can be retained in cytoplasm via YAP/TAZ interactions
- Activity-dependent shuttling: Neuronal activity influences nuclear-cytoplasmic distribution
TEAD1 participates in multiple feedback loops:
- Autoregulation of its own expression
- Regulation of Hippo pathway components
- Cross-talk with other transcription factor pathways
TEAD1 is implicated in AD through multiple mechanisms:
- Tau pathology: TEAD1-mediated transcription is disrupted by tau-induced alterations
- YAP dysregulation: Aβ exposure modulates Hippo pathway activity
- Synaptic dysfunction: TEAD1 regulates synaptic plasticity genes
- Neuronal survival: Pathway dysregulation leads to increased apoptosis
Hippo pathway dysregulation affects dopaminergic neurons:
- YAP/TAZ signaling altered in substantia nigra
- TEAD1 expression reduced in PD brain tissue
- Contributes to dopaminergic neuron vulnerability
TEAD1 contributes to neurodegeneration through several mechanisms:
- Apoptosis dysregulation: Altered TEAD1-mediated transcription affects pro-survival and pro-death gene balance
- Autophagy impairment: TEAD1 regulates autophagy-related genes; pathway dysfunction disrupts protein clearance
- Neuroinflammation: TEAD1 in glial cells modulates inflammatory responses
- Synaptic dysfunction: Loss of TEAD1 target gene regulation compromises synaptic plasticity
Several animal models have elucidated TEAD1 function:
- TEAD1 knockout mice: Embryonic lethal, cardiac defects
- Conditional KO models: Brain-specific deletion reveals neuronal functions
- YAP/TAZ double KO: Shows overlapping and unique functions with TEAD1
- Transgenic models: Expressing mutant TEAD1 recapitulates disease features
Targeting TEAD1 offers therapeutic potential:
- YAP-TEAD1 interaction inhibitors — Several compounds in development
- Gene therapy approaches — Viral vector delivery
- Small molecule modulators — Pathway-specific compounds
TEAD1 functions primarily through its partnership with YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif). This partnership is central to Hippo pathway signaling:
- Complex formation: YAP/TAZ bind to TEAD1 through specific protein domains
- Transcriptional activation: The complex binds to TEAD DNA response elements
- Coactivator recruitment: YAP/TAZ bring chromatin remodelers and transcriptional machinery
- Target gene expression: Genes controlling cell growth, survival, and differentiation are activated
The YAP-TEAD1 complex is regulated by Hippo pathway kinases LATS1/2, which phosphorylate YAP and TAZ, leading to their cytoplasmic retention and degradation.
¶ DNA Binding and Target Gene Specificity
TEAD1 recognizes specific DNA sequences:
- MCAT elements: TEAD1 binds the consensus 5'-CTTYWAY-3'
- Multiple binding sites: Different promoters contain varying numbers of TEAD binding sites
- Cofactor influence: Partner proteins modulate DNA binding affinity and specificity
- Tissue-specific targets: Different tissues show distinct TEAD1 target gene sets
TEAD1 controls numerous downstream targets:
- Proliferation genes: Cyclins, CDKs, growth factors
- Survival genes: Bcl-2, survivin, IAPs
- Differentiation factors: Developmental transcription factors
- Metabolic enzymes: Glycolysis and mitochondrial genes
- Extracellular matrix: Collagen, fibronectin components
¶ Brain Expression and Function
TEAD1 exhibits broad expression in the brain:
- Neurons: High expression in cortical and hippocampal neurons
- Astrocytes: Moderate expression in glial cells
- Oligodendrocytes: Lower expression in myelin-producing cells
- Neural stem cells: Active expression in proliferative zones
TEAD1 plays essential roles in neural development:
- Neural stem cell maintenance: Supports proliferation of progenitor cells
- Neuronal differentiation: Controls expression of differentiation markers
- Migration regulation: Modulates neuronal positioning in developing brain
- Cortical layering: Contributes to proper cortical architecture
TEAD1 is involved in synaptic plasticity:
- Synaptic protein regulation: Controls expression of synaptic components
- LTP induction: Required for long-term potentiation in hippocampus
- Memory formation: TEAD1 activity correlates with cognitive function
- Synapse stability: Maintains synaptic structure and function
In Alzheimer's disease, Aβ affects TEAD1 signaling:
- Aβ exposure reduces TEAD1 nuclear localization
- YAP/TAZ partitioning is altered in AD neurons
- TEAD1 target gene expression is dysregulated
- Contributes to neuronal vulnerability and death
TEAD1 intersects with tau pathology:
- Tau accumulation affects YAP/TAZ localization
- TEAD1-mediated transcription is perturbed
- Synaptic TEAD1 targets are downregulated
- Provides link between protein aggregation and transcriptional dysregulation
TEAD1 regulates inflammatory responses:
- Controls cytokine expression in glial cells
- Modulates microglial activation states
- Links inflammation to cell survival pathways
- Therapeutic targeting may provide anti-inflammatory benefits
¶ Axonal Growth and Regeneration
TEAD1 supports neuronal regeneration:
- Promotes axonal extension in developing neurons
- YAP/TEAD1 axis contributes to repair mechanisms
- Activity decreases with aging
- Enhancement strategies may improve regeneration after injury
Several approaches are being developed:
- YAP-TEAD interaction disruptors: Block protein-protein binding
- TEAD1 DNA binding inhibitors: Prevent target gene activation
- Hippo pathway activators: Upstream kinase agonists
Viral vector approaches include:
- YAP/TAZ modulation: Deliver modified transcription factors
- TEAD1 knockdown: Reduce pathway activity in disease states
- Combination approaches: Target multiple pathway components
¶ Biomarkers and Diagnostics
TEAD1 as a disease marker:
- Brain TEAD1 levels as biomarker for neurodegeneration
- YAP/TEAD1 ratio in CSF as potential indicator
- Expression changes correlating with disease stage
¶ Interactions and Signaling Network
TEAD1 interacts with multiple signaling pathways:
| Interactor |
Interaction Type |
Function |
| YAP |
Direct binding |
Transcriptional coactivation |
| TAZ |
Direct binding |
Transcriptional coactivation |
| LATS1/2 |
Upstream regulation |
Kinase-mediated inhibition |
| MST1/2 |
Upstream regulation |
Pathway activation |
| VGLL proteins |
Competition |
Modulates YAP binding |
| p300 |
Coactivator |
Chromatin remodeling |
¶ Axonal Growth and Regeneration
TEAD1 supports neuronal regeneration:
Several approaches are being developed:
Viral vector approaches include:
¶ Biomarkers and Diagnostics
TEAD1 as a disease marker:
- Brain TEAD1 levels as biomarker for neurodegeneration
- YAP/TEAD1 ratio in CSF as potential indicator
- Expression changes correlating with disease stage
¶ Interactions and Signaling Network
TEAD1 interacts with multiple signaling pathways:
| Interactor |
Interaction Type |
Function |
| YAP |
Direct binding |
Transcriptional coactivation |
| TAZ |
Direct binding |
Transcriptional coactivation |
| LATS1/2 |
Upstream regulation |
Kinase-mediated inhibition |
| MST1/2 |
Upstream regulation |
Pathway activation |
| VGLL proteins |
Competition |
Modulates YAP binding |
| p300 |
Coactivator |
Chromatin remodeling |
TEAD1 expression patterns show promise as diagnostic and prognostic biomarkers in neurodegeneration:
Brain tissue biomarkers: Immunohistochemical analysis of postmortem brain tissue reveals:
- Reduced TEAD1 nuclear localization in AD prefrontal cortex
- Altered YAP/TEAD1 ratio correlates with disease severity
- TEAD1 target gene expression predicts cognitive decline
Cerebrospinal fluid biomarkers: Emerging CSF markers include:
- Soluble TEAD1 fragments as neuronal damage indicators
- YAP/TEAD1 ratio in extracellular vesicles
- Correlation with established biomarkers (tau, Aβ42)
Blood-based biomarkers: Research is validating peripheral markers:
- TEAD1 mRNA in peripheral blood mononuclear cells
- YAP/TEAD1 balance as systemic indicator
Multiple therapeutic approaches are being developed to target TEAD1 and the Hippo pathway:
Several classes of compounds are in development:
-
YAP-TEAD interaction disruptors: Block the protein-protein interaction between YAP and TEAD1
- Verteporfin derivatives
- Peptide mimics of TEAD interaction domains
- Allosteric inhibitors
-
TEAD autacoid inhibitors: Target the palmitoylation of TEAD proteins
- FL-410 (in preclinical development)
- K-975 (shown to reduce tumor growth)
-
Hippo pathway activators: Target upstream kinases to restore pathway activity
- LATS1/2 activators
- MST1/2 agonists
Viral vector-mediated delivery offers another strategy:
- YAP overexpression: Deliver modified YAP variants with enhanced activity
- TEAD1 knockdown: Reduce pathological TEAD1 signaling using shRNA
- Combination therapy: Target multiple components of the pathway
Biologic approaches include:
- YAP mimetics: Engineered YAP variants that activate TEAD1
- Decoy proteins: Soluble TEAD1 extracellular domains
- Antibody-based inhibitors: Anti-YAP or anti-TEAD1 antibodies
TEAD1 is highly conserved across evolution:
| Species |
Identity |
Key Features |
| Human |
Reference |
Full-length protein |
| Mouse |
97% |
Conserved function |
| Zebrafish |
75% |
YAP/TAZ interaction |
| Drosophila |
60% |
Yorkie ortholog |
The TEA domain and YAP-binding region show the highest conservation, reflecting their essential functions.
The TEAD family arose from gene duplication events:
- Early metazoans: Single TEAD gene
- Vertebrates: Four family members (TEAD1-4)
- Specialized functions in different tissues
Multiple animal models illuminate TEAD1 function:
Zebrafish models: Transparent embryos enable real-time imaging of:
- Neural tube development
- Cell migration patterns
- YAP/TEAD1 dynamics
Mouse models:
- TEAD1 knockout: Embryonic lethal (E10.5-14.5)
- Conditional CNS knockout: Viable with neurological phenotypes
- Transgenic overexpression: Altered brain development
Invertebrate models: Drosophila Yorkie (YAP ortholog) enables:
- Rapid genetic screening
- Tissue-specific manipulation
- Live imaging of pathway dynamics
Primary neurons and cell lines provide mechanistic insights:
- Primary cortical neurons: Acute studies of YAP/TEAD1 dynamics
- iPSC-derived neurons: Patient-specific models
- Neuroblastoma lines: Stable transfection studies
- Organoid systems: Three-dimensional brain models
Key knowledge gaps remain:
- Cell-type specificity: How does TEAD1 function differ across neuronal subpopulations?
- Temporal dynamics: What is the precise timing of Hippo pathway dysregulation in disease?
- Crosstalk complexity: How does TEAD1 integrate signals from multiple pathways?
- Therapeutic window: When is the optimal time for intervention?
New frontiers include:
- Single-cell analysis: Understanding TEAD1 function in specific cell types
- Spatial transcriptomics: Mapping YAP/TEAD1 target genes in brain regions
- CRISPR screening: Identifying pathway modifiers and synthetic lethal interactions
- Protein structure: Developing high-resolution TEAD1-YAP structure for drug design
¶ Clinical Trial Landscape
Current and planned trials targeting the Hippo pathway:
| Agent |
Target |
Phase |
Indication |
| K-975 |
TEAD1 palmitoylation |
Preclinical |
Solid tumors |
| Verteporfin |
YAP-TEAD |
Preclinical |
Liver disease |
| MDM2 inhibitors |
YAP degradation |
Phase I |
Various |
While no clinical trials specifically target neurodegeneration yet, the strong biological rationale supports future development.
TEAD1 plays crucial roles in neural stem cell (NSC) function[@morita2022]:
¶ Stem Cell Maintenance
- Self-renewal: TEAD1 in NSC proliferation
- Fate decisions: TEAD1 in neuronal vs. glial lineage
- Aging: TEAD1 in age-related NSC decline
- Adult neurogenesis: TEAD1 in hippocampal neurogenesis
- Developmental neurogenesis: TEAD1 in embryonic brain
- Regeneration: TEAD1 in injury-induced neurogenesis
TEAD1 contributes to oligodendrocyte biology[@suzuki2023]:
- Oligodendrocyte differentiation: TEAD1 in lineage commitment
- Myelin formation: TEAD1 in myelination
- Node of Ranvier: TEAD1 in nodal complex
- Multiple sclerosis: TEAD1 in MS pathophysiology[@takahashi2023]
- Therapeutic potential: Targeting Hippo pathway for remyelination
TEAD1 in microglial biology[@chen2023]:
- Activation states: TEAD1 in microglial polarization
- Neuroinflammation: TEAD1-mediated inflammatory responses
- Brain homeostasis: TEAD1 in microglial surveillance
¶ TEAD1 in Aging and Neurodegeneration
- Expression decline: TEAD1 decreases with age
- Functional implications: Age-related TEAD1 dysfunction
- Neurodegeneration risk: Contribution to sporadic AD/PD
Targeting TEAD1 in aging[@yang2023]:
- Preventive strategies: Maintaining TEAD1 function
- Disease modification: Restoring Hippo pathway activity
- Combination approaches: TEAD1 with other targets
¶ TEAD1: Knowledge Gaps and Future Directions
- Cell-type specificity: How does TEAD1 function differ across specific brain cell types?
- Temporal dynamics: What is the precise timing of Hippo pathway dysregulation in disease?
- Crosstalk complexity: How does TEAD1 integrate signals from multiple pathways?
- Therapeutic targeting: Can TEAD1 be safely modulated?
- Biomarkers: Can TEAD1 be used as a disease biomarker?
- Single-cell analysis: Define TEAD1 function at single-cell resolution
- Spatial transcriptomics: Map TEAD1 target genes in brain
- CRISPR screening: Identify pathway modifiers
- Clinical translation: Develop TEAD1-targeted therapeutics